Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 29;8(1):10-41.
doi: 10.1021/acsomega.2c04078. eCollection 2023 Jan 10.

Advances in Lung Cancer Treatment Using Nanomedicines

Akshansh Sharma  1 , Devanshi Shambhwani  2 , Sadanand Pandey  3 , Jay Singh  4 , Hauzel Lalhlenmawia  5 , Murali Kumarasamy  6 , Sachin Kumar Singh  7   8 , Dinesh Kumar Chellappan  9 , Gaurav Gupta  10   11   12 , Parteek Prasher  13 , Kamal Dua  8   14 , Deepak Kumar  1
Affiliations
Review

Advances in Lung Cancer Treatment Using Nanomedicines

Akshansh Sharma et al. ACS Omega. .

Abstract

Carcinoma of the lungs is among the most menacing forms of malignancy and has a poor prognosis, with a low overall survival rate due to delayed detection and ineffectiveness of conventional therapy. Therefore, drug delivery strategies that may overcome undesired damage to healthy cells, boost therapeutic efficacy, and act as imaging tools are currently gaining much attention. Advances in material science have resulted in unique nanoscale-based theranostic agents, which provide renewed hope for patients suffering from lung cancer. Nanotechnology has vastly modified and upgraded the existing techniques, focusing primarily on increasing bioavailability and stability of anti-cancer drugs. Nanocarrier-based imaging systems as theranostic tools in the treatment of lung carcinoma have proven to possess considerable benefits, such as early detection and targeted therapeutic delivery for effectively treating lung cancer. Several variants of nano-drug delivery agents have been successfully studied for therapeutic applications, such as liposomes, dendrimers, polymeric nanoparticles, nanoemulsions, carbon nanotubes, gold nanoparticles, magnetic nanoparticles, solid lipid nanoparticles, hydrogels, and micelles. In this Review, we present a comprehensive outline on the various types of overexpressed receptors in lung cancer, as well as the various targeting approaches of nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Nanoparticles as an efficient carrier in the therapeutics of lung tumor.
Figure 2
Figure 2
Various nanocarrier-mediated drug delivery systems.
Figure 3
Figure 3
A unilamellar liposome nanoparticle. Lipophilic drugs are contained between the amphiphilic bilayer, while hydrophilic drugs are confined in the central core.
Figure 4
Figure 4
Structural representation of polymeric nanoparticles.
Figure 5
Figure 5
Demonstrated dendrimer generation.
Scheme 1
Scheme 1. Synthesis of G4SA-GFLG-DOX (Generation 4 Succinamic Acid PAMAM Dendrimer Conjugated with Doxorubicin)
DMF: dimethylformamide, EDC: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, and NHS: N-hydroxysuccinimide.
Figure 6
Figure 6
Structural representation of micelles.
Scheme 2
Scheme 2. Schematic Representation of DOX, FA, and DOTA-Gd-Conjugated β-CD-Based Micelles
Figure 7
Figure 7
Structural representation of a carbon nanotube.
Figure 8
Figure 8
Structural representation of gold nanoparticles.
Scheme 3
Scheme 3. Synthesis Scheme for Paclitaxel Incorporated with DNA-Linked Gold Nanoparticles
Figure 9
Figure 9
Effects shown by solid lipid nanoparticle-encapsulated drugs.
Figure 10
Figure 10
Structural representation of quantum dots.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fitzmaurice C.; Dicker D.; Pain A.; Hamavid H.; Moradi-Lakeh M.; MacIntyre M. F.; Allen C.; Hansen G.; Woodbrook R.; Wolfe C.; et al. The global burden of cancer 2013. JAMA Oncol 2015, 1, 505–527. 10.1001/jamaoncol.2015.0735. - DOI - PMC - PubMed
    1. Kumar S.; Sharma A. K.; Lalhlenmawia H.; Kumar D. Natural Compounds Targeting Major Signaling Pathways in Lung Cancer. Targeting Cellular Signalling Pathways in Lung Diseases 2021, 821–846. 10.1007/978-981-33-6827-9_37. - DOI
    1. Litzky L. A. Pulmonary sarcomatous tumors. Arch. Pathol. Lab. Med. 2008, 132, 1104–1117. 10.5858/2008-132-1104-PST. - DOI - PubMed
    1. Zorzetto M.; Ferrari S.; Saracino L.; Inghilleri S.; Stella G. M. MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications. Transl. Lung Cancer Res. 2012, 1, 194.10.3978/j.issn.2218-6751.2012.09.03. - DOI - PMC - PubMed
    1. Pikor L. A.; Ramnarine V. R.; Lam S.; Lam W. L. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung cancer 2013, 82, 179–189. 10.1016/j.lungcan.2013.07.025. - DOI - PubMed
-